The high frequency of an aberrant activation of the PI3K/Akt pathway in cancer cells and the observed consequences for cancer cell radiation resistance make Akt, its upstream regulators and specific downstream effectors interesting therapeutic targets for improving the therapy outcome. This evidence concerns the gene AKT1 and cancer.